Abstract
Background Metabolic syndrome (MetS) is a complex disorder that affects the cardiovascular system and it is generally associated with mental and metabolic health issues. To diagnose MetS it is essential to identify certain comorbidities related to cardiovascular diseases. Hypothyroidism, for instance, is a common disorder that reduces the basal metabolism, leading to the development of other diseases. Therefore, it is important to know how hypothyroidism can increase the chances of MetS.
Objectives To assess whether there is an increased risk of patients with hypothyroidism developing MetS given the association of different comorbidities in a sample of an urban Brazilian population.
Methods This was an observational, exploratory and retrospective study of patients diagnosed with hypothyroidism (using levothyroxine for hormonal reposition therapy).The incidence and prevalence of four specific comorbidities were quantified by histograms, and all comparisons were performed by using joint and conditional probabilities with their respective confident intervals.
Results Consistent with the literature, our results also showed that there is a prevalence in women (79%) and in elderly patients (80%). Moreover, it also indicated that around 64% of the patients were women aged over 60 years and at least one comorbidity was associated with them. By analyzing the risk group for MetS, with two comorbidities, the combination with higher chances of acquiring a new comorbidity were Systemic arterial hypertension (SAH) and Diabetes Mellitus (DM), in this sample.
Conclusion Our results indicate that hypothyroidism can increase the chances to develop MetS or may worsen its effects due to the association of common comorbidities present in both cases. Keywords: metabolic syndrome, hypothyroidism, comorbidities, statistical analysis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was partially funded by the federal Brazilian foundation "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" (CNPq).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was approved by the Research Ethics Committee, and its followed the ethical percepts of Brazilian Health National Council 466/2012, approval number CAAE ("Certificate of Ethical Appraisal Submission"): 45972615.6.0000.5559, sight number 1.112.225. Certificate of Approval Ethics Committee responsible: 5559 - Faculty of Medicine of Itajuba - FMIt Address: Av. Renno Junior, 368 - Building: Central dos Nucleos Telephone: (35) 3629-8728 E-mail: cep{at}fmit.edu.br Responsible Researcher: Paulo Jose Oliveira Cortez Date of Ethics Approval by CEP/CONEP: 06/17/2015
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data was collected by the clinicians and researchers from Medical Faculty of Medicine of Itajuba, at the University Hospital (ASSOCIACAO DE INTEGRACAO SOCIAL DE ITAJUBA). All the data are accessible under request.